Page 1265 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1226 Part ten Prevention and Therapy of Immunological Diseases

randomized trial of recombinant adenovirus HIV vaccine (Step Study). J 80. Matheron S, D’Ortenzio E, Leparc-Goffart I, et al. Long Lasting
Infect Dis 2012;206:258–66. Persistence of Zika Virus in Semen. Clin Infect Dis 2016;63:1264.
71. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with 81. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Island, Federated States of Micronesia. N Engl J Med 2009;360:
Med 2009;361:2209–20. 2536–43.
72. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of 82. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French polynesia,
an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275–86. South pacific, 2013. Emerg Infect Dis 2014;20:1085–6.
73. Corey L, Gilbert PB, Tomaras GD, et al. Immune correlates of vaccine 83. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and
protection against HIV-1 acquisition. Sci Transl Med 2015;7:310rv7. effectiveness of an rVSV-vectored vaccine expressing Ebola surface
74. Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr glycoprotein: interim results from the Guinea ring vaccination cluster-
Opin HIV AIDS 2013;8:326–32. randomised trial. Lancet 2015;386:857–66.
75. Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly 84. An Ebola vaccine: first results and promising opportunities. Lancet
neutralizing antibody VRC01 administration during chronic HIV-1 2015;386:830.
infection. Sci Transl Med 2015;7:319ra206. 85. Birkett AJ. Status of vaccine research and development of vaccines for
76. Ledgerwood JE, Coates EE, Yamshchikov G, et al. Safety, malaria. Vaccine 2016;34:2915–20.
pharmacokinetics and neutralization of the broadly neutralizing HIV-1 86. Hoffman SL, Vekemans J, Richie TL, et al. The March Toward Malaria
human monoclonal antibody VRC01 in healthy adults. Clin Exp Vaccines. Am J Prev Med 2015;49:S319–33.
Immunol 2015;182:289–301. 87. Evans TG, Schrager L, Thole J. Status of vaccine research and
77. Krammer F. Novel universal influenza virus vaccine approaches. Curr development of vaccines for tuberculosis. Vaccine 2016;34:2911–14.
Opin Virol 2016;17:95–103. 88. Hoft DF. Tuberculosis vaccine development: goals, immunological design,
78. Cho A, Wrammert J. Implications of broadly neutralizing antibodies in and evaluation. Lancet 2008;372:164–75.
the development of a universal influenza vaccine. Curr Opin Virol 89. Kaplan G. Rational vaccine development–a new trend in tuberculosis
2016;17:110–15. control. N Engl J Med 2005;353:1624–5.
78a. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant 90. Warfel JM, Edwards KM. Pertussis vaccines and the challenge of inducing
influenza vaccine in adults 50 years of age or older. N Engl J Med durable immunity. Curr Opin Immunol 2015;35:48–54.
2017;376:2427–36.
79. Interim Guidance for Zika Virus Testing of Urine - United States, 2016.
MMWR Morb Mortal Wkly Rep 2016;65:474.